The Scottish Medicines Consortium (SMC) has approved Mavenclad (cladribine) as a treatment for highly active relapsing multiple sclerosis.
News
-
-
Scientists experimenting with an innovative treatment for cancer have now devised a targeted injection that has already successfully eliminated tumours in mice.
-
February 07, 2018
The first ever patient to be treated with a new type of CAR-T cell therapy in a novel clinical trial is now in remission.
-
February 06, 2018
Remember the hypospray from Star Trek? Maybe it's close to reality.
-
February 02, 2018
A new combination of medicines is showing positive results in ER/HER2-Positive breast cancer.
-
The experimental drug from Roche (balovaptan) has now been given Breakthrough Therapy Designation, potentially placing the drug on a faster path to market as the first pharmacological treatment for autism spectrum disorder (ASD). Pharmatimes, 30/01/2018.
-
January 29, 2018
Following the EMA’s approval in late 2017, the FDA has now also approved Lutathera (lutetium Lu 177 dotatate) for certain digestive tract cancers.
-
January 29, 2018
The potential of neuroprotective agents for a whole new form of treatment.
-
January 26, 2018
A list of medicines TheSocialMedwork will soon be making available.
-
January 25, 2018
New test detects ovarian and 7 other cancers using simple blood sample.
-
Brentuximab vedotin (Adcetris) has now been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma (CTCL) who have had at least 1 prior systemic therapy.
-
January 18, 2018
Lynparza (olaparib) is the first PARP inhibitor approved to treat breast cancer, and the first medicine ever for metastatic breast cancer who have a “BRCA” gene mutation.
-
January 15, 2018
Ocrevus (ocrelizumab), the first ever FDA approved medicine for primary progressive MS has now also been approved by the EMA.
-
January 14, 2018
A new study found that cabozantinib (Cabometyx) was more effective than everolimus in advanced renal cell carcinoma and bone metastases.
-
January 07, 2018
Pembrolizumab showed positive results in heavily pretreated, PD-L1–positive advanced esophageal carcinoma.
-
Specific strains of intestinal bacteria can improve the response rate to immunotherapy for patients being treated for advanced melanoma.
-
December 30, 2017
Eight important updates in lung cancer.
-
December 21, 2017
Darzalex (daratumumab) combination under review as first-line option.
-
Immunotherapy nivolumab has been linked to HIV reservoir decrease in a lung cancer patient.
-
December 07, 2017
In a pilot study immunotherapy proved active in some patients with metastatic, trastuzumab (Herceptin)-resistant HER2-positive breast cancer.
-
December 06, 2017
Is there substance to the claims that it's a groundbreaking treatment?
-
December 02, 2017
Researchers are suggesting that metastatic tumours in the lung can be successfully eradicated using cryotherapy – literally turning the masses into ice balls that are then resorbed by the body.
-
December 01, 2017
The FDA has approved the first biosimilar for the treatment of certain breast and stomach cancers.
-
November 28, 2017
Mavenclad (cladribine) has become the multiple sclerosis therapy of choice for 1 in 5 neurologists in Germany and the UK. Meanwhile, many European neurologists wait for Ocrevus (ocrelizumab).
-
November 28, 2017
A phase 3 study on lung cancer showed that Imfinzi (durvalumab) as a consolidation therapy reduced the risk of the disease progressing by 48 percent.
-
FDA approves Juluca (dolutegravir and rilpivirine) for the maintenance treatment of certain patients with HIV-1 infection.
-
October 27, 2017
Introducing a breakthrough known as 'CT1812'
-
Ocrevus (ocrelizumab) was approved in the US by the FDA in March 2017 for the treatment of adults with relapsing or primary progressive forms of MS, based on three clinical trials.
-
July 19, 2017
As we await the arrival of edaravone to US pharmacies, patients can access edaravone now through TheSocialMedwork.
-
June 15, 2017
With recent drops in new HIV diagnoses being linked to buying PrEP through online buyers clubs, the addition of PrEP to the WHO's essential medicine list, and the recent approval of generic PrEP in the US - here’s what you need to know.